

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94419 A2

- (51) International Patent Classification⁷: C07K 16/18
- (21) International Application Number: PCT/EP01/06361
- (22) International Filing Date: 6 June 2001 (06.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00202016.2 7 June 2000 (07.06.2000) EP
- (71) Applicant (*for all designated States except US*):
VLAAMS INTERUNIVERSITAIR INSTITUUT
VOOR BIOTECHNOLOGIE VZW [BE/BE]; Rijnvis-
schestraat 120, B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GROOTEN, Johan
[BE/BE]; Violierstraat 23, B-9920 Lovendegem (BE).
SEHRA, Sarita [IN/IN]; Kortrijksesteenweg 502, B-9000
Gent (BE).
- (74) Common Representative: VLAAMS INTERUNIVER-
SITAIR INSTITUUT VOOR BIOTECHNOLOGIE
VZW; Rijnvischestraat 120, B-9052 Zwijnaarde (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/94419 A2

(54) Title: METHOD TO INDUCE THE TH1 IMMUNE RESPONSE

(57) Abstract: The present invention relates to a method to induce the CD4+ Th1 immune response, eventually combined with a repression of the Th2 mediated activities, comprising the administration of an IgG isotype antibody which is not an IgG1 isotype antibody. Preferentially said antibody is an IgG2a and/or IgG2b isotype anti-allergen antibody. The shift from a Th2 response towards a mixed Th1/Th2 response is particularly useful in the treatment of diseases such as asthma. Because the method described corrects the immuno-pathological cause of the disease, this is the polarised Th2 response against allergen, rather than its consequences, a sustained cure from asthma can be achieved instead of a transient reduction of symptoms.